Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.72 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.62 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.62 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.62 |
| ▸ | FLT1 | P17948 | 3/20 | 0.61 |
| ▸ | FLT4 | P35916 | 3/20 | 0.61 |
| ▸ | GAK | O14976 | 1/20 | 0.61 |
| ▸ | BMP4 | P12644 | 3/20 | 0.56 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.54 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.54 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.54 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.54 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.54 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14424408 | 0.91 | KDR (0.85) | KDRPRKAB1ACVR1TGFBR1FLT1 | |
| SCHEMBL7618559 | 0.85 | KDR (0.77) | KDRPRKAB1ACVR1TGFBR1FLT1 | |
| SCHEMBL7618521 | 0.85 | KDR (0.77) | KDRPRKAB1ACVR1TGFBR1FLT1 | |
| SCHEMBL5419064 | 0.84 | KDR (0.61) | KDRPRKAB1ACVR1TGFBR1FLT1 | |
| SCHEMBL7610636 | 0.84 | KDR (1.00) | KDRPRKAB1ACVR1TGFBR1FLT1 | |
| SCHEMBL14437843 | 0.83 | KDR (0.68) | KDRPRKAB1ACVR1TGFBR1FLT1 | |
| SCHEMBL5410390 | 0.82 | KDR (0.67) | KDRPRKAB1ACVR1TGFBR1FLT1 | |
| SCHEMBL7610618 | 0.82 | KDR (1.00) | KDRPRKAB1ACVR1TGFBR1FLT1 | |
| SCHEMBL5416682 | 0.82 | KDR (0.67) | KDRPRKAB1ACVR1TGFBR1FLT1 | |
| SCHEMBL23989007 | 0.80 | KDR (0.65) | KDRPRKAB1ACVR1TGFBR1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262199-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262199-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262199-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20060183755-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2006-08-17 | — | — | US | disclosed |
| WO-2004052286-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183755-A1 | Tyrosine kinase inhibitors | FLT1, FLT4, KDR | KDR 3/4885PRKAB1 583/4885ACVR1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.